Somatostatin outperformed its marketed derivatives octreotide and lanreotide in inhibiting Aβ42 amyloid aggregation, achieving 91% inhibition at 25 μM.
91% aggregation inhibitionSomatostatin outperformed all other cyclic peptides and the reference compound in blocking Aβ42 fibril formation
What the researchers found
Somatostatin inhibited Aβ42 fibrillogenesis by 91% at 25 μM, outperforming its derivatives octreotide and lanreotide as well as the reference inhibitor orange G (86%).
Why it matters
If somatostatin-based peptides can prevent amyloid aggregation, they could represent a new therapeutic approach for Alzheimer's disease using compounds already in clinical use for other conditions.
The numbers in context
Somatostatin: 91% Abeta42 fibrillogenesis inhibition at 25 mcM. d-Trp8-somatostatin: 74%. Octreotide and lanreotide: ~54%. Reference agent orange G: 86%. Tested at 1, 5, 10, and 25 mcM.
How the study worked
In vitro study testing somatostatin, d-Trp8-somatostatin, octreotide, and lanreotide on Aβ42 aggregation kinetics and cytotoxicity in mouse hippocampal HT22 cells.
Who was studied
Not applicable (Abeta42 aggregation study)
What this study cannot tell us
In vitro study — Aβ42 aggregation inhibition in a test tube does not guarantee brain delivery or clinical efficacy. Somatostatin does not easily cross the blood-brain barrier.
How to read the evidence
In vitro study — strong anti-aggregation data but clinical applicability depends on solving brain delivery challenges.
When this study was published
Published in 2025, contributing to the search for peptide-based Alzheimer's treatments.
The bigger picture
Repurposing existing peptide drugs for Alzheimer's could accelerate treatment development since safety profiles are already established.
Questions still open
- Can somatostatin or its derivatives be delivered to the brain effectively enough to inhibit amyloid aggregation in vivo?
- What is the mechanism of somatostatin's anti-aggregation effect?
Common questions
Could somatostatin drugs help with Alzheimer's?
What is amyloid-beta aggregation?
Read the original research
Investigating the Interactions of a Cyclic Peptide Hormone Somatostatin and Its Derivatives on Amyloid-Beta Aggregation.
ACS chemical neuroscience, 16(16), 3115-3126
Citation
Pham, Amy Trinh; Zhao, Yusheng; Oo, Amy; Hefny, Ahmed A; Ganesan, Aravindhan; Rao, Praveen P N. (2025). Investigating the Interactions of a Cyclic Peptide Hormone Somatostatin and Its Derivatives on Amyloid-Beta Aggregation.. ACS chemical neuroscience, 16(16), 3115-3126. https://doi.org/10.1021/acschemneuro.5c00044